Open AccessAdeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model
Author(s) -
Sung Yi Hong,
Myun Hee Lee,
KyungSup Kim,
Hyun Cheol Jung,
Jae Kyung Roh,
Woo Jin Hyung,
Sung Hoon Noh,
Seung Ho Choi
Publication year - 2004
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v10.i8.1191
Subject(s) - endostatin , etoposide , camptothecin , topoisomerase inhibitor , genetic enhancement , cancer research , pharmacology , adeno associated virus , topoisomerase , combination therapy , in vivo , medicine , biology , microbiology and biotechnology , chemotherapy , in vitro , angiogenesis , gene , vector (molecular biology) , recombinant dna , biochemistry
rAAV mediated endostatin gene therapy has been examined as a new method for treating cancer. However, a sustained and high protein delivery is required to achieve the desired therapeutic effects. We evaluated the impact of topoisomerase inhibitors in rAAV delivered endostatin gene therapy in a liver tumor model.